Published in Vaccine Weekly, July 26th, 2006
Study 1: Amyloid load was reduced using an anti-A-beta single-chain antibody in an Alzheimer mouse model.
According to recent research from the United States, "Parenteral immunization of transgenic mouse models of Alzheimer disease (AD) with synthetic amyloid beta-peptide (A-beta) prevented or reduced A-beta deposits and attenuated their memory and learning deficits. A clinical trial of immunization with synthetic A-beta, however, was halted due to brain inflammation, presumably induced by a toxic A-beta, T-cell- and/or Fc-mediated immune response. Another issue...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly